Full Breakdown
FDA's Recent Actions on Leucovorin and Novo Nordisk: A Comprehensive Overview
3/15/2026, 5:12:19 AM
FDA Approval of Leucovorin for Rare Condition
On March 10, 2026, the U.S. Food and Drug Administration (FDA) approved leucovorin, a medication previously used to mitigate chemotherapy side effects, for the treatment of cerebral folate deficiency caused by a genetic mutation in the folate receptor 1 gene (FOLR1). This condition, which affects fewer than one in a million people, can lead to neurological symptoms that may resemble autism, such as speech difficulties and seizures. FDA Commissioner Marty Makary described the approval as a significant milestone for patients with this rare genetic disorder, emphasizing that it does not extend to broader autism treatment.
Background on Leucovorin's Controversial Promotion
The approval follows a controversial September 2025 announcement by President Donald Trump and FDA officials, who suggested that leucovorin could benefit a large number of children with autism. At that time, Makary claimed that the drug might help "hundreds of thousands" of children, a statement that sparked significant public interest and a subsequent 71% increase in prescriptions for the drug among children aged 5 to 17. However, the FDA later clarified that the evidence supporting leucovorin's efficacy for autism was insufficient, leading to disappointment among families who had hoped for broader access.
Criticism and Official Responses
Experts and medical organizations, including the American Academy of Pediatrics, have cautioned against the use of leucovorin for autism, citing limited evidence and potential side effects. Dr. Alycia Halladay of the Autism Science Foundation stated, "There is no evidence to say that leucovorin will help most people with autism, and there’s certainly no evidence to say it’s safe." The FDA's decision to narrow the approval to cerebral folate deficiency reflects a commitment to evidence-based medicine, despite the earlier promotional claims.
Novo Nordisk's Warning Letter from the FDA
In a separate but related development, the FDA issued a warning letter to Novo Nordisk on March 5, 2026, for failing to report serious adverse drug experiences associated with its GLP-1 medications, including semaglutide (Ozempic and Wegovy). The letter highlighted systemic failures in the company's safety reporting processes, including the failure to investigate and report three patient deaths, one of which involved suicide. The FDA noted that these violations could compromise the agency's ability to monitor drug safety effectively.
Implications for the Pharmaceutical Industry
Both the approval of leucovorin for a rare condition and the warning letter to Novo Nordisk underscore the FDA's evolving stance on drug approvals and safety monitoring. The agency's recent actions reflect a stringent approach to ensuring that medications are supported by robust scientific evidence, particularly for rare diseases. This scrutiny may impact future drug development and approval processes, especially for treatments targeting rare conditions.
What's Next?
As the FDA continues to navigate the complexities of drug approvals and safety monitoring, the pharmaceutical industry may face increased pressure to provide comprehensive data supporting the efficacy and safety of their products. The ongoing scrutiny of Novo Nordisk's practices may lead to further regulatory actions if the company fails to address the issues outlined in the warning letter adequately. Meanwhile, the fate of leucovorin as a treatment for autism remains uncertain, with experts urging caution and further research before any broader applications are considered.
